NFKB1 and inflammatory bowel disease: The anti‐inflammatory cytokine interleukin‐10 (IL‐10) modulates sphingolipid metabolism to attenuate nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB)‐mediated inflammation, thereby increasing the risk of inflammatory bowel disease (Ryan and Zanoni 2024).